Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada.
Department of Geography, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada.
BMC Public Health. 2021 Jul 1;21(1):1285. doi: 10.1186/s12889-021-11282-x.
In Canada, the legalization of cannabis has enabled cannabidiol (CBD) to become a popular commercial product, increasingly used for medical or therapeutic purposes. There are currently over one thousand CBD products available globally, ranging from oil extracts to CBD-infused beverages. Despite increased usage and availability, the evidence supporting the medical efficacy of CBD is limited. Anecdotal evidence suggests CBD sellers represent their products for medical use through direct medical claims or advice, which in Canada, is not allowed under the Cannabis Act without Health Canada approval. However, it is not clear the extent of sellers making health claims or other strategies used to promote medical usage of CBD. The objective of this study is to determine how CBD sellers advertise their products online to consumers.
The product descriptions of 2165 CBD products from 70 websites selling CBD products for human consumption in Canada were collected from January 14th 2020 to February 2nd 2020 using an automated website scraper tool. A framing analysis was used to determine how CBD sellers frame their products to prospective customers. The specific medical conditions CBD is represented to treat and product forms were tabulated.
CBD products are framed to prospective customer through three distinct frames: a specific cure or treatment (n = 1153), a natural health product (n = 872), and a product used in certain ways to achieve particular results (n = 1388). Product descriptions contained medical or therapeutic claims for 171 medical conditions and ailments, with 53.3% of products containing at least one claim. The most prevalent claims found in product descriptions were the ability to treat or manage pain (n = 824), anxiety (n = 609), and inflammation (n = 545). Claims were found for treating or managing serious and-life-threatening illnesses such as multiple sclerosis (n = 210), arthritis (n = 179), cancer (n = 169), Crohn's disease (n = 78), Parkinson's disease (n = 59), and human immunodeficiency virus (HIV) (n = 54). CBD most often came in oil/tincture/concentrate form (n = 755), followed by edibles (n = 428), and vaporizer pen/cartridge/liquid products (n = 290).
The findings suggest CBD is represented as a medical option for numerous conditions and ailments. We recommend Health Canada to conduct a systematic audit of companies selling CBD for regulatory adherence.
在加拿大,大麻合法化使大麻二酚(CBD)成为一种流行的商业产品,越来越多地用于医疗或治疗用途。目前,全球有超过一千种 CBD 产品,从油提取物到 CBD 注入饮料。尽管使用率和可用性都有所增加,但支持 CBD 医学疗效的证据有限。传闻证据表明,CBD 卖家通过直接医疗声明或建议来代表其产品用于医疗用途,而在加拿大,未经加拿大卫生部批准,根据《大麻法》是不允许的。然而,目前尚不清楚卖家做出健康声明的程度或其他用于推广 CBD 医疗用途的策略。本研究的目的是确定 CBD 卖家如何在网上向消费者宣传其产品。
使用自动网站抓取工具,于 2020 年 1 月 14 日至 2 月 2 日期间,从加拿大销售供人类食用的 CBD 产品的 70 个网站中收集了 2165 种 CBD 产品的产品说明。使用框架分析来确定 CBD 卖家如何向潜在客户推销他们的产品。列出了 CBD 代表治疗的特定医疗条件和产品形式。
CBD 产品通过三个不同的框架向潜在客户推销:特定的治疗或治疗(n=1153)、天然健康产品(n=872)和以特定方式使用以达到特定效果的产品(n=1388)。产品说明包含了 171 种医疗条件和疾病的医疗或治疗声明,其中 53.3%的产品至少包含一项声明。产品描述中发现的最常见的声明是能够治疗或管理疼痛(n=824)、焦虑(n=609)和炎症(n=545)。发现了用于治疗或管理多发性硬化症(n=210)、关节炎(n=179)、癌症(n=169)、克罗恩病(n=78)、帕金森病(n=59)和人类免疫缺陷病毒(HIV)(n=54)等严重危及生命的疾病的声明。CBD 最常以油/酊剂/浓缩物的形式出现(n=755),其次是可食用产品(n=428)和蒸发器笔/墨盒/液体产品(n=290)。
调查结果表明,CBD 被视为许多疾病和病症的医疗选择。我们建议加拿大卫生部对销售 CBD 的公司进行监管合规性的系统审计。